Artelo Biosciences, Inc.
ARTL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,612 | $7,617 | $17,225 | $3,433 |
| - Cash | $1,720 | $2,066 | $746 | $2,338 |
| + Debt | $954 | $878 | $95 | $104 |
| Enterprise Value | $2,846 | $6,429 | $16,574 | $1,199 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$3,009 | -$3,149 | -$2,379 | -$3,812 |
| % Margin | – | – | – | – |
| Net Income | -$3,120 | -$3,221 | -$2,372 | -$3,778 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.97 | -5.61 | -0.72 | -7 |
| % Growth | 29.2% | -679.2% | 89.7% | – |
| Operating Cash Flow | -$3,498 | -$514 | -$1,597 | -$2,567 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,498 | -$514 | -$1,597 | -$2,567 |